COVID-19 vaccines

Abstract

Within a year, several vaccines against COVID-19 could be developed. In Western countries, RNA vaccines were initially licensed, and some vector vaccines are also already available or well advanced in clinical trials. All data available so far show a high protective efficacy of the first vaccines. Adverse effects are predominantly mild to moderate and rapidly reversible. Serious thrombotic complications with thrombocytopenia have occurred in very rare cases after the vector vaccines from AstraZeneca and Janssen / Johnson & Johnson. Allergic reactions have been observed after all vaccines, they can very rarely also take a serious course. Persons who have previously had a serious allergic reaction to vaccines, drugs or food must not be vaccinated. A vaccination rate that is now high in Germany and other countries has contributed significantly to a decrease in the incidence of SARS-CoV-2 infections in recent months.